The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•25 February 2026•

1 min read

Novo Nordisk Slashes Wegovy Price by 50% Amid Sharp Stock Decline

FDA and Novo Nordisk logos above a laboratory scene with computer monitors, chemical structures, medicine bottles, and pills.

Key Facts

1Novo Nordisk has slashed the price of its weight-loss drug Wegovy by half.

2The company's stock has dropped 22% in the past week and 56% over the past year.

Novo Nordisk has announced a significant 50% price reduction for its popular weight-loss medication, Wegovy. This strategic move comes as the pharmaceutical giant faces mounting political and regulatory pressure regarding drug pricing. The price cut coincides with a period of severe market volatility for the company, with its stock price plunging 22% over the past week. Over the last year, NVO shares have lost approximately 56% of their value, currently trading near their 52-week lows. Analysts suggest that while the price reduction may address regulatory concerns, it poses a substantial threat to future profit margins and revenue growth. Investors remain cautious as the company navigates these headwinds in a highly competitive weight-loss drug market.